Cardiogen: Comprehensive Research Overview
Document Version: 2.0
Last Updated: January 2026
Classification: Research Paper - Khavinson Bioregulator Peptides
1. Executive Summary
Cardiogen is a short peptide bioregulator with primary effects on fibroblasts, the cells responsible for tissue repair and scar formation. Its biggest benefits appear in heart attack, hypertension, and chronic heart failure settings.
Cardiovascular Applications
Target Conditions:
- Post-myocardial infarction recovery
- Chronic heart failure management
- Hypertensive heart disease
- Age-related cardiac function decline
Proposed Mechanisms:
- Fibroblast activity regulation (reduced excessive scarring)
- Cardiomyocyte protection via epigenetic modulation
- Restoration of cardiac tissue gene expression
- Anti-fibrotic effects in heart tissue
Khavinson Bioregulator Platform
Cardiogen developed by Dr. Vladimir Khavinson as tissue-specific bioregulator:
- Short peptide (2-4 amino acids)
- Targets cardiac fibroblasts and cardiomyocytes
- Epigenetic regulation of gene expression
Evidence Quality
- Preclinical Cardiac Protection: MODERATE - Russian animal studies showing reduced infarct size
- Human Heart Failure: LOW - Limited Western peer-reviewed trials
- Mechanism Validation: LOW - Epigenetic claims not rigorously demonstrated
- Long-Term Safety: LOW - Insufficient data
Status: Research supplement in Russia; not approved for cardiac indications in Western medicine
2. Molecular Identity & Mechanism
Peptide Structure
Cardiogen is a synthetic tetrapeptide with the amino acid sequence:
- Sequence: H-Ala-Glu-Asp-Arg-OH (AEDR)
- Molecular Weight: ~475 Da
- Classification: Khavinson bioregulator peptide
Mechanisms of Action
Gene and Protein Regulation
Cardiogen binds to specific DNA sequences and modulates gene expression in cardiac tissue. This epigenetic regulation supports:
- Cardiomyocyte differentiation and proliferation
- Contractile protein synthesis (actin, myosin)
- Cytoskeletal and nuclear matrix protein activation
Anti-Apoptotic Effects
Cardiogen reduces programmed cell death in cardiac tissue by:
- Downregulating p53 protein expression
- Preserving cardiomyocyte viability under ischemic stress
- Reducing necrotic zones after cardiac injury
Research demonstrated that "the tetrapeptide cardiogen demonstrated the great stimulating effect on the proliferation both in tissues from young and old rats."
Fibroblast Modulation
Cardiogen exhibits dual action on cardiac fibroblasts:
- Suppresses excessive fibroblast proliferation - reducing pathological scar formation
- Promotes beneficial ECM synthesis - collagen and elastin for tissue integrity
- Net effect: Reduced cardiac remodeling toward heart failure
Cardioprotective Outcomes
Studies suggest:
- Threefold reduction in mortality after experimental cardiac injury
- Reduced necrotic zones in cardiac tissue
- Improved myocardial contractility
3. Goal Archetype Integration
Primary Goal Alignment
| Goal | Relevance | Role of Cardiogen |
|---|
| Fat Loss | None | No direct metabolic effect |
| Muscle Building | None | Cardiac-specific, not skeletal muscle |
| Longevity | High | Addresses age-related cardiac decline through cellular regeneration |
| Healing/Recovery | High | Primary application - post-MI recovery, cardiac tissue repair |
| Cognitive Optimization | Low | Indirect via improved cardiac output and cerebral perfusion |
| Hormone Optimization | None | No endocrine effects |
Secondary Goal Alignments
| Goal | Relevance | Mechanism |
|---|
| Cardioprotection | Primary | Direct action on cardiomyocytes and fibroblasts |
| Anti-Fibrotic | High | Reduces excessive scar formation in heart tissue |
| Cardiovascular Resilience | High | Supports adaptation to cardiac stress |
| Post-Surgery Recovery | Moderate | May support recovery after cardiac procedures |
When Cardiogen Makes Sense
- Post-myocardial infarction recovery - Primary application; reduces scar formation and supports regeneration
- Chronic heart failure management - Addresses cardiac remodeling pathways
- Hypertensive heart disease - Supports cardiac tissue under chronic pressure load
- Age-related cardiac decline - Preventive application in middle-aged and elderly populations
- Post-cardiac surgery - Theoretical support for tissue healing
- High-stress cardiovascular occupations - Athletes, first responders with cardiac demands
When to Choose Something Else
- Acute cardiac emergencies - Cardiogen is not emergency intervention; seek immediate medical care
- Arrhythmia management - No evidence for electrical conduction effects
- Vascular disease without cardiac involvement - Consider Vesugen for vessel-specific support
- General wellness without cardiac concerns - More appropriate bioregulators exist for other organs
- Concurrent anticoagulation therapy - Insufficient interaction data warrants caution
4. Dosing Protocols
Standard Dosing (Oral Capsules)
| Parameter | Recommendation | Notes |
|---|
| Daily Dose | 1-2 capsules, 1-2x daily | 20-40mg peptide complex per day |
| Timing | With meals | Improves absorption |
| Cycle Length | 20-30 days | Standard course duration |
| Repeat Interval | Every 4-6 months | Cycling approach for sustained benefit |
Age-Stratified Dosing
| Age Bracket | Starting Dose | Adjustment | Rationale |
|---|
| 35-50 | 1 capsule 2x/day | Standard | Preventive maintenance; normal clearance |
| 50-65 | 1-2 capsules 2x/day | May increase based on response | Higher need due to age-related cardiac changes |
| 65-75 | 1 capsule 2x/day | Conservative start | Slower clearance; assess tolerance |
| 75+ | 1 capsule 1x/day | Lower dose; extend cycle | Reduced elimination; potential drug interactions |
Note: Cardiogen is primarily indicated for middle-aged and elderly populations where age-related cardiac decline becomes relevant.
Sex-Specific Considerations
Males:
- Standard dosing applies
- Monitor in context of testosterone status (TRT may influence cardiac remodeling)
- Higher baseline cardiovascular risk warrants earlier consideration
Females:
- Standard dosing applies
- Post-menopausal women have increased cardiovascular risk - appropriate timing for Cardiogen
- No known hormone-specific interactions
Condition-Specific Dosing
| Condition | Protocol Modification |
|---|
| Post-MI Recovery | Consider higher end of range (2 capsules 2x/day) for initial course |
| Chronic Heart Failure | Standard dose; may repeat courses more frequently (every 3-4 months) |
| Prevention/Maintenance | Lower end of range; standard 4-6 month cycling |
| Post-Cardiac Surgery | Initiate 2-4 weeks post-procedure after medical clearance |
5. Drug Interactions - Comprehensive
Critical Context
Limited Formal Data: Cardiogen lacks FDA approval and formal drug interaction studies. Recommendations below are based on:
- Mechanism-based theoretical interactions
- Practitioner observations
- General principles for cardiac patients
General Recommendation: Consult with a cardiologist before combining Cardiogen with any cardiac medications.
Prescription Medications - Cardiac
| Drug Class | Interaction | Severity | Management |
|---|
| Beta-Blockers (metoprolol, carvedilol) | Theoretical additive cardioprotection | Minor | Monitor; generally compatible |
| ACE Inhibitors (lisinopril, enalapril) | Theoretical additive remodeling benefits | Minor | Monitor; may be synergistic |
| ARBs (losartan, valsartan) | Theoretical additive remodeling benefits | Minor | Monitor; may be synergistic |
| Calcium Channel Blockers | No known interaction | Minor | Standard monitoring |
| Digoxin | Theoretical enhanced inotropic effect | Moderate | Monitor digoxin levels; watch for toxicity signs |
| Statins | No known pharmacokinetic interaction | Minor | Continue standard statin therapy |
| Diuretics | No direct interaction | Minor | Monitor electrolytes, hydration |
Anticoagulants and Antiplatelets
| Drug | Interaction | Severity | Management |
|---|
| Warfarin | No known direct interaction; cardiac patients often on warfarin | Moderate | More frequent INR monitoring when starting Cardiogen |
| DOACs (apixaban, rivaroxaban) | No known interaction | Minor | Standard monitoring |
| Aspirin | No known interaction | Minor | Continue standard antiplatelet therapy |
| Clopidogrel | No known interaction | Minor | Continue standard therapy |
| Dual Antiplatelet Therapy | No known interaction | Minor | Monitor for bleeding as baseline |
Important: While no direct interactions are documented, cardiac patients on anticoagulation require close monitoring when adding any new agent.
Antiarrhythmics
| Drug | Interaction | Severity | Management |
|---|
| Amiodarone | No known interaction; both used in cardiac contexts | Moderate | Monitor thyroid function, QT interval |
| Sotalol | No known interaction | Minor | Standard monitoring |
| Flecainide | No known interaction | Minor | Standard monitoring |
Diabetes Medications (Cardiac Context)
| Drug | Interaction | Severity | Management |
|---|
| Metformin | No known interaction | Minor | Continue; monitor glucose |
| SGLT2 Inhibitors (empagliflozin) | Theoretical synergy - both cardioprotective | Minor | May be beneficial combination |
| GLP-1 Agonists | No known interaction | Minor | Continue standard therapy |
| Insulin | No known interaction | Minor | Standard glucose monitoring |
Other Compounds (Stacking)
| Compound | Interaction | Effect | Recommendation |
|---|
| Vesugen (vascular bioregulator) | Synergistic | Enhanced cardiovascular support | Recommended combination for comprehensive CV health |
| Vilon (immune bioregulator) | Synergistic | Combined immune + cardiac support | Good for systemic recovery protocols |
| Thymogen (thymus bioregulator) | Synergistic | Immune balance + cardiac | Useful in post-cycle therapy (PCT) |
| BPC-157 | Synergistic | Full-body healing | Compatible; enhances overall recovery |
| TB-500 | Synergistic | Angiogenesis + cardiac support | Good for athletes; improved vessel formation |
| Epithalon (pineal bioregulator) | Synergistic | Longevity + cardiac health | Foundation of Khavinson protocols |
Supplements
| Supplement | Interaction | Notes |
|---|
| CoQ10 | Synergistic | Supports mitochondrial cardiac function |
| Omega-3 Fatty Acids | Synergistic | Anti-inflammatory; cardioprotective |
| Magnesium | Supportive | Essential for cardiac function |
| L-Carnitine | Supportive | Cardiac energy metabolism |
| Vitamin D | Supportive | Cardiovascular health association |
| Hawthorn | Caution | May potentiate cardiac effects; monitor |
| Nattokinase | Caution | Fibrinolytic; monitor if on anticoagulants |
Foods/Timing
| Food/Timing | Interaction | Notes |
|---|
| With meals | Preferred | Improved absorption |
| Grapefruit | No known interaction | Not CYP3A4 substrate |
| High-sodium foods | Monitor | Cardiac patients should limit sodium regardless |
| Alcohol | Limit | Cardiovascular stress; limit intake |
6. Bloodwork Impact & Monitoring
Cardiac Biomarker Context
Understanding cardiac markers in the context of Cardiogen use:
| Marker | Normal Range | What It Measures | Cardiogen Relevance |
|---|
| BNP | <100 pg/mL (acute); <35 pg/mL (non-acute) | Ventricular wall stress | May improve over time if reducing cardiac stress |
| NT-proBNP | <300 pg/mL (acute); <125 pg/mL (non-acute) | Ventricular wall stress (longer half-life) | Trend monitoring preferred |
| Troponin I/T | <0.04 ng/mL (varies by assay) | Myocardial injury | Should NOT increase; elevation warrants evaluation |
| hs-CRP | <1 mg/L (optimal); <3 mg/L (average) | Systemic inflammation | May decrease with cardioprotection |
| Homocysteine | <10 umol/L (optimal) | Cardiovascular risk marker | Monitor as part of complete CV panel |
Expected Marker Changes
| Marker | Expected Change | Direction | Timeline |
|---|
| BNP/NT-proBNP | Potential improvement in chronic heart failure | ↓ | 2-3 months |
| Troponin | Should remain stable | ↔ | Continuous |
| hs-CRP | May decrease with reduced inflammation | ↓ | 4-8 weeks |
| Ejection Fraction (Echo) | Potential improvement | ↑ | 3-6 months |
Monitoring Schedule
| Timepoint | Required Tests | Optional Tests |
|---|
| Baseline | CBC, BMP, BNP/NT-proBNP, hs-CRP, Troponin | Lipid panel, Echo |
| 4-6 weeks | BNP/NT-proBNP, Troponin | hs-CRP |
| 3 months | CBC, BMP, BNP/NT-proBNP, hs-CRP | Lipid panel, Echo if indicated |
| Ongoing | BNP/NT-proBNP every 3-6 months | Annual Echo for chronic conditions |
Red Flags in Labs
| Finding | Action |
|---|
| Troponin elevation | Stop Cardiogen; seek immediate cardiac evaluation |
| BNP >500 pg/mL (new or worsening) | Evaluate for decompensated heart failure |
| New anemia (Hgb drop >2 g/dL) | Evaluate for GI bleeding if on anticoagulants |
| Creatinine rise >50% from baseline | Evaluate kidney function; may indicate cardiac output decline |
| Elevated liver enzymes >3x ULN | Evaluate for hepatic congestion from heart failure |
Labs + Symptoms Integration
| Lab Finding | Symptom | Interpretation | Action |
|---|
| Rising BNP | Increasing dyspnea | Heart failure decompensation | Medical evaluation; adjust HF therapy |
| Stable BNP | Improved exercise tolerance | Positive response | Continue protocol |
| Troponin elevation | Chest pain | Possible ACS | Emergency evaluation |
| Stable troponin | Chest pain | Non-cardiac etiology likely | Evaluate other causes |
| Low BNP | Persistent fatigue | Non-cardiac fatigue | Evaluate thyroid, anemia, etc. |
7. Protocol Integration
Stacking with Other Bioregulators
Recommended Cardiac Stack (Khavinson Protocol)
| Stack | Rationale | Protocol Notes |
|---|
| Cardiogen + Vesugen | Heart muscle + blood vessels | Comprehensive cardiovascular support; run concurrently |
| Cardiogen + Epithalon | Cardiac + pineal (longevity foundation) | Khavinson emphasized pineal as fundamental to all protocols |
| Cardiogen + Vilon | Cardiac + immune | Post-infection recovery; systemic support |
| Cardiogen + Thymogen | Cardiac + thymus | Post-illness; immune-cardiac integration |
Performance/Recovery Stack
| Stack | Rationale | Protocol Notes |
|---|
| Cardiogen + BPC-157 | Cardiac protection + systemic healing | Athletes with high cardiac demands |
| Cardiogen + TB-500 | Cardiac + angiogenesis | Enhanced vessel formation; endurance athletes |
Comprehensive Longevity Stack
| Stack | Rationale | Protocol Notes |
|---|
| Cardiogen + Epithalon + Vesugen + Vilon | Multi-organ longevity approach | Khavinson's comprehensive aging protocol |
Timing Considerations
| If Also Taking | Timing with Cardiogen |
|---|
| Other oral bioregulators | Can take together with meals |
| Beta-blockers | No specific timing needed |
| Thyroid medication | Separate by 1 hour |
| Warfarin | Take at consistent times; monitor INR |
| BPC-157 (injectable) | Different administration routes; no timing conflict |
Integration with Lifestyle Pillars
| Pillar | Integration Point |
|---|
| Nutrition | Mediterranean diet supports cardiovascular health; omega-3 rich foods enhance effects; limit sodium |
| Activity | Cardiac rehabilitation exercises appropriate; avoid overexertion during initial protocol; zone 2 cardio optimal |
| Stress Management | High cortisol worsens cardiac outcomes; meditation, breathing exercises support protocol |
| Sleep | Quality sleep essential for cardiac repair; 7-9 hours recommended |
Cycling Protocols
Standard Prevention Cycle:
- 20-30 day course
- Repeat every 4-6 months
- Prevents tolerance development
Intensive Recovery Cycle (Post-MI/Surgery):
- 30 day course
- 30 days off
- Repeat for 3 cycles
- Then transition to standard prevention
Maintenance Phase:
- After initial therapeutic courses
- 20 day course every 6 months
- Ongoing cardiovascular support
8. Safety Profile
Reported Side Effects
Cardiogen has demonstrated a favorable safety profile:
| Side Effect | Frequency | Notes |
|---|
| Individual intolerance | Rare | Discontinue if occurs |
| Mild GI discomfort | Rare | Usually transient |
| Injection site reaction (injectable forms) | Rare | If using injectable preparation |
Contraindications
| Condition | Status | Rationale |
|---|
| Known hypersensitivity | Contraindicated | Allergic reaction risk |
| Active malignancy | Use with caution | Theoretical concern: Cardiogen promotes cell proliferation; however, research suggests differential effect (induces apoptosis in tumor cells) |
| Pregnancy/Lactation | Avoid | Insufficient safety data |
| Pediatric use | Not recommended | Developed for age-related conditions |
Monitoring Requirements
- Baseline and periodic cardiac biomarkers (BNP, troponin)
- Standard cardiovascular monitoring for underlying conditions
- Report any new symptoms to healthcare provider
9. Research Limitations
Current Evidence Gaps
- Most studies conducted in animal models or in vitro
- Limited Western peer-reviewed human trials
- Epigenetic mechanisms not rigorously validated
- Long-term safety data insufficient
- No formal drug interaction studies
Research Status
| Aspect | Evidence Level | Notes |
|---|
| Preclinical cardiac protection | Moderate | Russian animal studies |
| Human heart failure | Low | Limited Western trials |
| Mechanism validation | Low | Theoretical basis strong |
| Long-term safety | Low | Insufficient data |
Stacking Insights
- ust trashes you. And M C is a peptide. And they are spectacularly different.
- Let me just go over mod so you actually have a baseline and then you can go all right where do I go with this. Dr. T. Okay. So forget everything about hormones.
References
- Khavinson, V. Peptide bioregulators - 40 years of research. St. Petersburg Institute of Bioregulation and Gerontology.
- Peptide Sciences. Cardiogen 20mg Bioregulator product information.
- Edge Peptides. What are Khavinson Peptides? An Intro to Peptide Bioregulators.
- Atlas of Science. Cardiomyocyte Metabolism Research and Cardiogen Peptide.
- American College of Cardiology. Cardiac Biomarkers and Heart Failure. 2015.
- PMC. Monitoring of biomarkers in heart failure. 2019.
Document Prepared By: Research Team, Epiq Aminos